Genetic Variation of Neurogenin 3 is Slightly Associated with Hyperproinsulinaemia and Progression Toward Type 2 Diabetes

Abstract

Objective: Transcription factor Neurogenin 3 (NGN3) is considered as a candidate gene for the development of type 2 diabetes. The aim of the current study was to investigate the relevance of NGN3 variants for the clinical spectrum of diabetes development and disease progressions.

Research Design and Methods: A total of 552 subjects with increased risk of type 2 diabetes were investigated. They underwent a 75 g OGTT with measurements of plasma glucose, insulin and proinsulin at fasting and at 30, 60, 90 and 120 minutes after the glucose challenge, repeated after 3 years. The NGN3 SNPs, Gly167Arg and Ser199Phe were genotyped.

Result: Patients with type 2 diabetes carrying the variant genotype at SNP199 presented with significantly higher proinsulin levels. Proinsulin level was also associated with progression of diabetes mellitus. There was a discrete association of the Ser199Phe variant with evolution of the disease status.

Conclusion: A genetic variation in NGN3 gene may be among the genetic determinants involved in the pathogenesis of diabetes.

Key words

Neurogenin 3 - proinsulin - progression of type 2 diabetes

References

• 1 Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.  Lancet. 1999;  354 ((9179)) 617-621
• 2 Apelqvist A, Li H. et al . Notch signalling controls pancreatic cell differentiation.  Nature. 1999;  400 ((6747)) 877-881
• 3 Bornstein SR, Schuppenies A. et al . Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions.  Mol Psychiatry. 2006;  11 ((10)) 892-902
• 4 Bornstein SR, Wong ML. et al . 150 years of Sigmund Freud: What would Freud have said about the obesity epidemic?.  Mol Psychiatry. 2006;  11 ((12)) 1070-1072
• 5 Bosque-Plata L del, Lin J. et al . Mutations in the coding region of the neurogenin 3 gene (NEUROG3) are not a common cause of maturity-onset diabetes of the young in Japanese subjects.  Diabetes. 2001;  50 ((3)) 694-696
• 6 Fisher EB, Walker EA. et al . Behavioral science research in the prevention of diabetes : status and opportunities.  Diabetes care. 2002;  25 ((3)) 599-606
• 7 Gradwohl G, Dierich A. et al . Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas.  Proc Natl Acad Sci USA. 2002;  97 ((4)) 1607-1611
• 8 Hampe CS, Wallen AR. et al . Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic beta cell mass.  Exp Clin Endocrinol Diabetes. 2005;  113 ((7)) 381-387
• 9 Hani EH, Stoffers DA. et al . Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus.  J Clin Invest. 1999;  104 ((9)) R41-8
• 10 Jenny M, Uhl C. et al . Neurogenin3 is differentially required for endocrine cell fate specification in the intestinal and gastric epithelium.  Embo J. 2002;  21 ((23)) 6338-6347
• 11 Jensen J, Heller RS. et al . Independent development of pancreatic alpha- and beta-cells from neurogenin3-expressing precursors: a role for the notch pathway in repression of premature differentiation.  Diabetes. 2000;  49 ((2)) 163-176
• 12 Jensen JN, Hansen L. et al . Polymorphisms in the neurogenin 3 gene (NEUROG) and their relation to altered insulin secretion and diabetes in the Danish Caucasian population.  Diabetologia. 2001;  44 ((1)) 123-126
• 13 Kasznicki J, Blasiak J. et al . The Trp64Arg beta3-adrenergic receptor amino-acid variant is not associated with overweight and type 2 diabetes mellitus in Polish population.  Exp Clin Endocrinol Diabetes. 2005;  113 ((10)) 593-597
• 14 Kiessling A, Ehrhart-Bornstein M. Transcription factor 7-like 2 (TCFL2) - a novel factor involved in pathogenesis of type 2 diabetes.  , Comment on: Grant et al., Nature Genetics 2006, Published online 15 January 2006 Horm Metab Res. 2006;  38 ((2)) 137-138
• 15 Kim SHJ, Warram H. et al . Mutation screening of the neurogenin-3 gene in autosomal dominant diabetes.  J Clin Endocrinol Metab. 2001;  86 ((5)) 2320-2322
• 16 Korenblum W, Barthel A. et al . Elevated cortisol levels and increased rates of diabetes and mood symptoms in Soviet Union-born Jewish immigrants to Germany.  Mol Psychiatry. 2005;  10 ((11)) 974-975
• 17 Lee CS, Leon DD De. et al . Regeneration of pancreatic islets after partial pancreatectomy in mice does not involve the reactivation of neurogenin-3.  Diabetes. 2006;  55 ((2)) 269-272
• 18 Lee CS, Perreault N. et al . Neurogenin 3 is essential for the proper specification of gastric enteroendocrine cells and the maintenance of gastric epithelial cell identity.  Genes Dev. 2002;  16 ((12)) 1488-1497
• 19 Macfarlane WM, Frayling, TM. et al . Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes.  J Clin Invest. 1999;  104 ((9)) R33-9
• 20 Malecki MT, Jhala US. et al . Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus.  Nat Genet. 1999;  23 ((3)) 323-328
• 21 Maraninchi M, Bourcigaux N. et al . A novel mutation (E333D) in the thyroid hormone beta receptor causing resistance to thyroid hormone syndrome.  Exp Clin Endocrinol Diabetes. 2006;  114 ((10)) 569-576
• 22 Okada T, Tobe K. et al . Variants of neurogenin 3 gene are not associated with Type II diabetes in Japanese subjects.  Diabetologia. 2001;  44 ((2)) 241-244
• 23 Olckers A, Towers GW. et al . Protective effect against type 2 diabetes mellitus identified within the ACDC gene in a black South African diabetic cohort.  Metabolism. 2007;  56 ((5)) 587-592
• 24 Reichel A, Schwarz J. et al . Depression and anxiety symptoms in diabetic patients on continuous subcutaneous insulin infusion (CSII).  Mol Psychiatry. 2005;  10 ((11)) 975-976
• 25 Schulze MB, Hoffmann K. et al . An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes.  Diabetes Care. 2007;  30 ((3)) 510-515
• 26 Schwarz P. High risk strategy in diabetes prevention - pro.  Deutsche Medizinische Wochenschrift. 2005;  130 ((17)) 1103
• 27 Schwarz PE. Report from the Congress of the American Diabetes Association (ADA): Orlando 2005-65th Annual Scientific Sessions in San Diego, CA, USA, June 10th-14th 2005.  Exp Clin Endocrinol Diabetes. 2005;  113 ((8)) 475-9
• 28 Schwarz PE. Congress report from the American Diabetes Association 66th Annual Scientific Sessions in Washington, USA.  Exp Clin Endocrinol Diabetes. 2006;  114 ((10)) 605-610
• 29 Schwarz PE, Bornstein SR. Pre-diabetes metabolic syndrome in Germans.  Horm Metab Res. 2006;  38 ((5)) 359
• 30 Schwarz PE, Govindarajalu S. et al . Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population.  Horm Metab Res. 2006;  38 ((7)) 447-451
• 31 Schwarz PE, Schwarz J. et al . Diabetes prevention - from physiology to implementation.  Horm Metab Res. 2006;  38 ((7)) 460-464
• 32 Schwarz PE, Schwarz J. et al . Development of a diabetes prevention management program for clinical practice.  Public Health Rep. 2007;  122 ((2)) 258-263
• 33 Schwarz PE, Towers GW. et al . Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter.  Diabetes Care. 2006;  29 ((7)) 1645-1650
• 34 Schwarz PEH, Horikawa Y. et al . Genetic variation of CAPN10 affects susceptibility to type 2 diabetes in German and Czech population.  Diabetes. 2001;  50 A232
• 35 Schwarz PEH, Peltonen M. Prevention of type 2 diabetes - lessons we have learned for implementation.  Horm Metab Res. in press 2007; 
• 36 Schwitzgebel VM, Scheel DW. et al . Expression of neurogenin3 reveals an islet cell precursor population in the pancreas.  Development. 2000;  127 ((16)) 3533-3542
• 37 Sommer L, Ma Q. et al . neurogenins, a novel family of atonal-related bHLH transcription factors, are putative mammalian neuronal determination genes that reveal progenitor cell heterogeneity in the developing CNS and PNS.  Mol Cell Neurosci. 1996;  8 ((4)) 221-241
• 38 Trajkovski M, Mziaut H. et al . Genes of type 2 diabetes in beta cells.  Endocrinol Metab Clin North Am. 2006;  35 ((2)) 357-369
• 39 Tsuchiya T, Schwarz PE. et al . Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses.  Mol Genet Metab. 2006;  89 ((1-2)) 174-184
• 40 Wang J, Cortina G. et al . Mutant neurogenin-3 in congenital malabsorptive diarrhea.  N Engl J Med. 2006;  355 ((3)) 270-280
• 41 Wareham NJ, Byrne CD. et al . Fasting proinsulin concentrations predict the development of type 2 diabetes.  Diabetes Care. 1999;  22 ((2)) 262-270
• 42 Zimmet P, Alberti KG. et al . Global and societal implications of the diabetes epidemic.  Nature. 2001;  414 ((6865)) 782-787

Correspondence